GlycoNex Inc

GlycoNex operates with a market price of 22.5 TWD and a market cap of 2.53 billion TWD, trading at a price-to-book ratio of 2.58 and a price-to-tangible-book ratio of 2.58. The company's enterprise value to revenue ratio is 69.72, while its enterprise value to EBITDA is negative at -10.57, reflecting its current unprofitability. The company's liquidity position is mixed, with a current ratio of 8.0 but negative free cash flow of -207.62 million TWD and negative operating cash flow of -166.29 million TWD. The debt-to-equity ratio is 0.48, indicating moderate leverage. Profitability metrics are weak, with a return on equity of -23.95% and a return on assets of -15.13%. These figures are below the industry median for biotechnology firms, which typically exhibit positive ROIC and ROE in growth phases. The company's operating margin is -66.0%, and its net margin is -62.1%, both significantly below the industry median for biotechnology firms. The gross margin of 62.2% is relatively strong but insufficient to offset the high R&D and SG&A expenses. GlycoNex's revenue is concentrated in its domestic market and the rest of Asia, with no disclosed segment breakdown. The company does not provide geographic revenue distribution in its latest filings, but its operations are primarily based in Taiwan. There is no indication of significant diversification or international expansion beyond Asia. The company's growth trajectory is uncertain, with a current FY revenue outlook of 37.86 million TWD and a next FY revenue estimate of 51.00 million TWD. This represents a projected increase of 34.7% year-over-year, but the company is expected to remain unprofitable, with a net income of -235.23 million TWD in the current FY and an estimated -212.00 million TWD in the next FY. The mean EPS estimate is -1.86 TWD, compared to the last actual EPS of 2.16 TWD, indicating a significant earnings contraction. Risk factors include liquidity constraints, with negative free cash flow and operating cash flow, and a net cash position that is negative after subtracting total debt. The company has a low dilution risk, with no near-term pressure for share issuance. However, the risk assessment flags the company's liquidity as medium, and the current ratio of 8.0 suggests that short-term obligations are covered, but the negative cash flows could impact long-term stability. Recent events include analyst estimates that are uniformly set at 33.50 TWD for the price target, with a mean EPS estimate of -1.86 TWD. The company's last actual EPS was 2.16 TWD, indicating a significant earnings contraction. There are no recent filings or transcripts provided in the input data to assess management commentary or strategic shifts.